CN102018666A - 一种喷昔洛韦注射液的制备方法及临床新用途 - Google Patents
一种喷昔洛韦注射液的制备方法及临床新用途 Download PDFInfo
- Publication number
- CN102018666A CN102018666A CN 201010284029 CN201010284029A CN102018666A CN 102018666 A CN102018666 A CN 102018666A CN 201010284029 CN201010284029 CN 201010284029 CN 201010284029 A CN201010284029 A CN 201010284029A CN 102018666 A CN102018666 A CN 102018666A
- Authority
- CN
- China
- Prior art keywords
- penciclovir
- injection
- preparation
- aminoacid
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001179 penciclovir Drugs 0.000 title claims abstract description 87
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 239000007924 injection Substances 0.000 title claims abstract description 55
- 238000002347 injection Methods 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 239000000243 solution Substances 0.000 title abstract description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000001014 amino acid Nutrition 0.000 claims abstract description 24
- 229940024606 amino acid Drugs 0.000 claims abstract description 24
- 150000001413 amino acids Chemical class 0.000 claims abstract description 24
- 239000004475 Arginine Substances 0.000 claims abstract description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004472 Lysine Substances 0.000 claims abstract description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000004279 alanine Nutrition 0.000 claims abstract description 5
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 5
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 5
- 239000004220 glutamic acid Substances 0.000 claims abstract description 5
- 239000004474 valine Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 241000701806 Human papillomavirus Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 208000001688 Herpes Genitalis Diseases 0.000 claims description 14
- 201000004946 genital herpes Diseases 0.000 claims description 14
- 239000004471 Glycine Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 238000004090 dissolution Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 7
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 7
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 229960003104 ornithine Drugs 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 206010059313 Anogenital warts Diseases 0.000 abstract description 29
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- BRPTUOYNOCSFRJ-FYZOBXCZSA-N sodium (2S)-4-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)butan-1-olate Chemical compound [Na+].Nc1nc(=O)c2ncn(CC[C@H](CO)C[O-])c2[nH]1 BRPTUOYNOCSFRJ-FYZOBXCZSA-N 0.000 description 14
- 239000008354 sodium chloride injection Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 229960002449 glycine Drugs 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000019802 Sexually transmitted disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229940075882 denavir Drugs 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012675 alcoholic extract Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000008400 supply water Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 208000028110 viral sexually transmitted disease Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102840299A CN102018666B (zh) | 2010-09-17 | 2010-09-17 | 一种喷昔洛韦注射液的制备方法及临床新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102840299A CN102018666B (zh) | 2010-09-17 | 2010-09-17 | 一种喷昔洛韦注射液的制备方法及临床新用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102018666A true CN102018666A (zh) | 2011-04-20 |
CN102018666B CN102018666B (zh) | 2011-12-21 |
Family
ID=43860721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102840299A Active CN102018666B (zh) | 2010-09-17 | 2010-09-17 | 一种喷昔洛韦注射液的制备方法及临床新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102018666B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042574A (zh) * | 2014-07-01 | 2014-09-17 | 哈药集团生物工程有限公司 | 一种含有更昔洛韦的冻干药物组合物及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524530A (zh) * | 2003-09-16 | 2004-09-01 | 湖北丽益医药科技有限公司 | 更昔洛韦静脉注射液的制备方法 |
-
2010
- 2010-09-17 CN CN2010102840299A patent/CN102018666B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524530A (zh) * | 2003-09-16 | 2004-09-01 | 湖北丽益医药科技有限公司 | 更昔洛韦静脉注射液的制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042574A (zh) * | 2014-07-01 | 2014-09-17 | 哈药集团生物工程有限公司 | 一种含有更昔洛韦的冻干药物组合物及制备方法 |
CN104042574B (zh) * | 2014-07-01 | 2016-07-06 | 哈药集团生物工程有限公司 | 一种含有更昔洛韦的冻干药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102018666B (zh) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014059880A1 (zh) | 一种制备治疗妇科炎症的石榴皮多酚凝胶剂的方法 | |
CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
CN106511512A (zh) | 一种中药外用凝胶及其制备方法与应用 | |
WO2013071696A1 (zh) | 人体五种正常碱基在制备肿瘤药物中的应用 | |
CN102018666B (zh) | 一种喷昔洛韦注射液的制备方法及临床新用途 | |
WO2019214723A1 (zh) | 绿原酸及其组合物在制备治疗鳞状细胞癌的药物中的用途 | |
CN101791392A (zh) | 药物组合物的用途 | |
GB2039736A (en) | Pharmaceutical compositions containing thiazolidine-4-carboxylic acid and method of preparation | |
CN1299275A (zh) | 减弱阴道酸度及治疗阴道炎的药物及其用途 | |
WO2022037362A1 (zh) | 一种治疗带状疱疹的注射剂 | |
US7262170B2 (en) | Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
EP2509586B1 (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
US20150352063A1 (en) | Drug for Killing Acid-Fast (Red) Bacillus | |
CN114404565B (zh) | β-苦瓜素在制备抗人乳头瘤病毒感染药物中的应用 | |
CN105147709B (zh) | 一种替诺福韦二吡呋酯或其药用盐的用途 | |
WO2011103794A1 (zh) | 用于治疗人乳头瘤病毒感染引起的疾病的喷剂及其制备方法 | |
CN112546202A (zh) | 一种具有抑制hpv病毒功能的复合剂及其制备方法 | |
CN107412241B (zh) | 一种紫丁香苷药物组合物及其在治疗宫颈炎中的应用 | |
CN111870689A (zh) | 一种纳豆激酶在治疗骨质疏松药物中的应用 | |
WO2006053487A1 (fr) | Utilisation de derives vegetaux de l’anthraquinone et de polysaccharides vegetaux destines au traitement du virus de l’immunodeficience humaine (vih) | |
CN109381466A (zh) | 促进糖尿病病人伤口愈合的治疗剂 | |
US20110136837A1 (en) | Mucoadhesive buccal tablets for the treatment of orofacial herpes | |
WO2019104587A1 (zh) | 一种药物组合物及其用途 | |
CA2115045C (en) | Composition for curing proliferative skin diseases | |
CN108114021A (zh) | 一种用于治疗病毒性疱疹的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Xi'an Xintong Pharmaceutical Research Co., Ltd. Assignor: Zhang Dengke Contract record no.: 2011610000058 Denomination of invention: Preparation method and new clinic application of penciclovir injection solution License type: Exclusive License Open date: 20110420 Record date: 20110629 |
|
ASS | Succession or assignment of patent right |
Owner name: XI'AN XINTONG MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG DENGKE Effective date: 20111008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 XI'AN, SHAANXI PROVINCE TO: 710077 XI'AN, SHAANXI PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20111008 Address after: 710077 C, block 2, room 69, pioneer research and Development Park, 205 Kam Yip Road, hi tech Zone, Shaanxi, Xi'an Applicant after: Xi'an Xintong Pharmaceutical Research Co., Ltd. Address before: 710075, Shaanxi Xi'an hi tech Zone, Kam Yip Road, 69, entrepreneurship research and Development Park, block C, 2 Applicant before: Zhang Dengke |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190704 Address after: 274000 No. 99 Kunming Road, Heze Mudan Industrial Park, Shandong Province Patentee after: SHANDONG DANHONG PHARMACEUTICAL CO., LTD. Address before: 710077 Room 205, 2nd Floor, Block C, Venture Development Park, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee before: Xi'an Xintong Pharmaceutical Research Co., Ltd. |
|
TR01 | Transfer of patent right |